NASDAQ:GLPG Galapagos (GLPG) Stock Price, News & Analysis $27.58 -0.59 (-2.09%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$27.54▼$28.3050-Day Range$24.20▼$30.0652-Week Range$24.16▼$42.46Volume150,952 shsAverage Volume132,600 shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/APrice Target$34.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Galapagos alerts: Email Address Galapagos MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside25.1% Upside$34.50 Price TargetShort InterestBearish2.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth-98.78%From $0.82 to $0.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector831st out of 910 stocksPharmaceutical Preparations Industry385th out of 426 stocks 2.8 Analyst's Opinion Consensus RatingGalapagos has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageGalapagos has only been the subject of 1 research reports in the past 90 days.Read more about Galapagos' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.34% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Galapagos has recently increased by 2.03%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGalapagos does not currently pay a dividend.Dividend GrowthGalapagos does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLPG. Previous Next 2.8 News and Social Media Coverage News SentimentGalapagos has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Galapagos this week, compared to 2 articles on an average week.Search Interest2 people have searched for GLPG on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Galapagos to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galapagos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Galapagos is held by insiders.Percentage Held by InstitutionsOnly 32.46% of the stock of Galapagos is held by institutions.Read more about Galapagos' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galapagos are expected to decrease by -98.78% in the coming year, from $0.82 to $0.01 per share.Price to Book Value per Share RatioGalapagos has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galapagos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Galapagos Stock (NASDAQ:GLPG)Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Read More GLPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLPG Stock News HeadlinesSeptember 3, 2024 | markets.businessinsider.comMorgan Stanley Remains a Hold on Galapagos (GLPG)September 3, 2024 | globenewswire.comGalapagos receives transparency notification from FMR LLCSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 2, 2024 | nz.finance.yahoo.comGalapagos NV (GXE.BE)September 1, 2024 | finance.yahoo.comEven after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five yearsAugust 26, 2024 | benzinga.comGalapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On MondayAugust 26, 2024 | msn.comMajor Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'August 26, 2024 | investors.comGalapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some CaveatsSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 23, 2024 | seekingalpha.comGalapagos: CAR-T Biotech To Change Landscape With GLPG5101 And BeyondAugust 23, 2024 | msn.comGalapagos gains after FDA nod for lymphoma trialAugust 23, 2024 | markets.businessinsider.comFDA Clears Galapagos' IND Application For Phase 1/2 Study Of GLPG5101 In R/R Non-Hodgkin LymphomaAugust 23, 2024 | globenewswire.comGalapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphomaAugust 21, 2024 | msn.comBelgium shares higher at close of trade; BEL 20 up 0.73%August 21, 2024 | finanznachrichten.deGalapagos NV: Galapagos receives transparency notification from FMR LLCAugust 21, 2024 | msn.comBelgium stocks higher at close of trade; BEL 20 up 0.73%August 20, 2024 | globenewswire.comGalapagos receives transparency notification from FMR LLCAugust 20, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: Baxter International (BAX), Galapagos (GLPG)See More Headlines Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2019Today9/07/2024Next Earnings (Estimated)9/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLPG CUSIPN/A CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,123Year Founded1999Price Target and Rating Average Stock Price Target$34.50 High Stock Price Target$38.00 Low Stock Price Target$31.00 Potential Upside/Downside+25.1%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio10.05 Quick Ratio9.87 Sales & Book Value Annual Sales$261.40 million Price / Sales6.95 Cash Flow$0.62 per share Price / Cash Flow44.72 Book Value$47.56 per share Price / Book0.58Miscellaneous Outstanding Shares65,897,000Free Float63,979,000Market Cap$1.82 billion OptionableOptionable Beta0.22 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Paulus A. Stoffels M.D. (Age 62)Ph.D., CEO, Chairman, Interim Head of R&D Comp: $1.34MMr. Thad Huston (Age 53)Executive VP, CFO & COO Ms. Sofie Van GijselHead of Investor RelationsMs. Valeria Cnossen (Age 50)Executive VP & General Counsel Marieke VermeerschHead of Corporate CommunicationMs. Annelies Missotten (Age 51)Executive VP & Chief Human Resources Officer Ms. Ellen Van Der AarHead of DevelopmentMr. Philippe Alen M.B.A.Ph.D., Pharm.D., Senior VP & Head of Business DevelopmentMr. Dirk De NaeyerHead of Development OperationsMs. Alice DietrichHead of Medical AffairsMore ExecutivesKey CompetitorsLantheusNASDAQ:LNTHAscendis Pharma A/SNASDAQ:ASNDRevolution MedicinesNASDAQ:RVMDViking TherapeuticsNASDAQ:VKTXBridgeBio PharmaNASDAQ:BBIOView All CompetitorsInstitutional OwnershipStonepine Capital Management LLCBought 91,366 shares on 8/21/2024Ownership: 0.736%Creative PlanningBought 18,407 shares on 8/16/2024Ownership: 0.028%Millennium Management LLCBought 17,089 shares on 8/15/2024Ownership: 0.518%DME Capital Management LPBought 75,000 shares on 8/15/2024Ownership: 0.356%Marshall Wace LLPBought 12,715 shares on 8/14/2024Ownership: 0.019%View All Institutional Transactions GLPG Stock Analysis - Frequently Asked Questions How have GLPG shares performed this year? Galapagos' stock was trading at $40.65 on January 1st, 2024. Since then, GLPG stock has decreased by 32.2% and is now trading at $27.58. View the best growth stocks for 2024 here. How were Galapagos' earnings last quarter? Galapagos NV (NASDAQ:GLPG) issued its earnings results on Thursday, February, 21st. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.82. What is Onno van de Stolpe's approval rating as Galapagos' CEO? 6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Galapagos IPO? Galapagos (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are Galapagos' major shareholders? Galapagos' top institutional investors include Primecap Management Co. CA (1.09%), Stonepine Capital Management LLC (0.74%), Millennium Management LLC (0.52%) and Renaissance Technologies LLC (0.41%). How do I buy shares of Galapagos? Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galapagos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV) and Biogen (BIIB). This page (NASDAQ:GLPG) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.